Clinical Trial Update: ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma [Phase 2]

View source ↗

Summary

This clinical trial update outlines the Phase 2 ELDORADO study, comparing Elranatamab versus Daratumumab each in combination with RVd Lite, for newly diagnosed …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Daratumumab (daratumumab)
• Elranatamab (elranatamab)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Multiple Myeloma, Newly Diagnosed Multiple Myeloma | Phase 2 | Status: NOT_YET_RECRUITING